Latest Listings And Ipos News

Sequoia Financial Group reported steady revenue but a sharp profit decline in FY25, driven by divestments and goodwill impairment. The company simplified its business structure and strengthened governance while maintaining dividend payouts.

Westgold Resources has declared a strong final dividend for FY25 and unveiled an enhanced dividend policy alongside a significant share buy-back program, signaling robust confidence in its growth and cash flow outlook.

Austral Gold Limited reported a net loss of US$1.3 million for the first half of 2025, while completing refurbishment of its Casposo plant to diversify production. Despite operational challenges and increased costs, the company leans on shareholder support and strategic investments to manage liquidity pressures.

Hartshead Resources has voluntarily suspended trading on the ASX pending a significant announcement about a well carry agreement linked to its P2607 Licence. The suspension is set to last until the announcement or early September.

Terra Metals has raised $15 million through an institutional placement led by cornerstone investors to fast-track exploration and development at its polymetallic Dante Project in Western Australia.

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Pengana Capital Group reported a strong turnaround in FY 2025 profitability, driven by a surge in private credit funds under management and successful new product launches. The firm’s strategic shift towards private markets is reshaping its revenue profile and balance sheet strength.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Pengana Capital Group Limited has reported a strong turnaround for FY2025, posting a $2.61 million profit after tax and a 42% increase in revenue to $60.5 million, driven by growth in private credit and performance fees.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.